An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing

Swiss Medical Weekly

Volumn 133, Issue 21-22, 2003, Pages 302-309

  Leuppi, Jörg D ^a   Salzberg, Marc ^b   Meyer, L ^a   Bucher, S E ^b   Nief, M ^c   Brutsche, Martin H ^a   Tamm, Michael ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b MyoContract   (Switzerland)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Adjustable dosing; Asthma; Budesonide; Formoterol; Inhaled corticosteroid; Long acting 2 agonist; Single inhaler

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; LONG ACTING DRUG; TERBUTALINE;

ADOLESCENT; ADULT; AGED; AROUSAL; ARTICLE; ASTHMA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG UTILIZATION; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HEARING LOSS; HOARSENESS; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; INHALER; LONG TERM CARE; LOW DRUG DOSE; LUNG FUNCTION TEST; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTIC SYNDROME; OPEN STUDY; OUTCOMES RESEARCH; PARALLEL DESIGN; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCORING SYSTEM; SYMPTOM; THRUSH; TREATMENT FAILURE;

EID: 0041366026     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. National Heart, Lung, and Blood Institute. Guidelines for the Diagnosis and Management of Asthma. Washington DC; 1997 7/97. Report No: 97-4051.
2. Leuppi JD, Downie SR, Salome CM, Jenkins CR, Woolcock AJ. A single high dose of inhaled corticosteroids: a possible treatment of asthma exacerbation. Swiss Med Wkly 2002; 132:7-11.
3. Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control, On behalf of the Italian Study Group. Chest 2000;117:440-6.
4. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344:219-24.
5. Woolcock AJ, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-8.
6. Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-11.
7. Roth M, Johnson PR, Rudiger JJ, King GG, Ge Q, Burgess JK, et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002;360:1265-6.
8. Reddel HK, Jenkins CR, Marks GB, Ware SI, Xuan W, Salome CM, et al. Optimal asthma control, starting with high doses of inhaled budesonide. Eur Respir J 2000;16:226-35.
9. Leuppi JD, Salome CM, Jenkins CR, Anderson SD, Xuan W, Marks GB, et al. Predictive markers of asthma exacerbation during stepwise dose-reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001;163:406-12.
10. Kemp JP, Cook DA, Incaudo GA, Corren J, Kalberg C, Emmett A, et al. Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. J Allergy Clin Immunol 1998;101:188-95.
11. Ringdal N, Chapman KR, Backer V, et al. Asthma control with salmeterol and fluticasone propionate (50/250 mcg) given twice daily in a single combination Diskus (Accuhaler) inhaler compared to salmeterol 50 mcg and fluticasone propionate 250 mcg given twice daily via two separate Diskus inhalers. Eur Resp J 1998;12(Suppl 28):PO330.
12. Kips JC, O'Connor BJ, Inman MD, Svensson K, Pauwels RA, O'Byrne PM. A long-term study of the anti-inflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161:996-1001.
13. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. Am J Respir Crit Care Med 2001;164:1392-7.
14. Volovitz B, Nussiniovitch M, Finkelstein Y, Harel L, Varsano I. Effectiveness of inhaled corticosteroids in controlling acute asthma exacerbations in children at home. Clin Pediatr (Phila) 2001;40:79-86.
15. Juniper EF, Guyatr GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999;14:32-8.
16. Brand PLP, Duiverman EJ, Postma DS, Waalkens HJ, Kerrebijen KF, van Essen-Zandvliet EEM, et al. Peak flow variation in childhood asthma: relationship to symptoms, atopy, airways obstruction and hyperresponsiveness. Eur Respir J 1997;10: 1242-7.
17. Reddel HK, Ware SI, Salome CM, Marks GB, Jenkins CR, Woolcock AJ. Standardization of ambulatory peak flow monitoring: the importance of recent β-agonist inhalation. Eur Respir J 1998;12:309-14.
18. Bowker AH. A test for symmetry in contingency tables. Am Stat Assoc J 1948;43:572-4.
19. Lemanske RF, Sorkness CA, Manger EA, Lazarus SC, Boushey HA, Fahy JV, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol. JAMA 2001;285:2594-603.
20. Tschopp JM, Frey JG, Pernet R, Burrus C, Jordan B, Morin A, et al. Bronchial asthma and self-management education: implementation of Guidelines by an interdisciplinary programme in health network. Swiss Med Wkly 2002;132:92-7.
21. Global strategy for asthma management and prevention. WHO/NHLBI workshop report. National Institutes of Health, National Heart, Lung and Blood Institute. Publication number 02-3659, 2002.
22. British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). Thorax 2003;58(Suppl 1):1-94.